Back to search

Switzerland· 67046001

Zeposia 0.23 mg, Hartkapseln

A ozanimod product containing ozanimodum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AE02

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedZeposia 0.23 mg, HartkapselnATCL04AE02REGISTER NO.67046001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ozanimod is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AE02 (ozanimod), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Ozanimod · ATC L04AE02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ozanimod costs, country by country.

Normalised to the WHO defined daily dose (0.92 mg), so markets compare like for like.

  • Switzerland: $85.78 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ozanimod · price per daily dose (0.92 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$85.78
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
ozanimodum
Manufacturer
Bristol-Myers Squibb SA
Country
Switzerland (CH)
ATC code
L04AE02
ATC class
Ozanimod
Defined daily dose
0.92 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680670460019
    Blist 7 Stk
    CHF 336.1

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

852 interactions on record for ozanimod.

Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ozanimod · interactions on record

852 records

  • 578 severe
  • 271 moderate
  • 3 minor

Most severe, free to view

  • FamotidineA02BA03severe
  • PapaverineA03AD01severe
  • IsomethepteneA03AX10severe
  • CisaprideA03FA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b02ea58e-852c-4727-b356-c5b14dafb4a2
GET /v1/drugs/b02ea58e-852c-4727-b356-c5b14dafb4a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "ozanimodum 0.46 mg",
  "valid_from": "2023-09-01",
  "limitations": "[{\"description\":\"Behandlung von schubförmig remittierender multipler Sklerose (MS). Erstverschreibung durch den Facharzt FMH für Neurologie.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21065.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21065.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2023-09-01\"},{\"description\":\"ZEPOSIA ist zur Behandlung von erwachsenen Patienten mit mittelschwerer bis schwerer aktiver Colitis Ulcerosa (CU) indiziert, die entweder auf konventionelle Therapien oder die Behandlung mit einem Biologikum ungenügend angesprochen haben, nicht mehr ansprechen oder die Therapie nicht tolerierten.<br>\\nBei Patienten, bei denen bis zur Woche 10 kein klinisches Ansprechen festzustellen ist, sollte die Therapie abgebrochen werden.<br>\\nDie Anwendung von ZEPOSIA in Kombination mit biologischen Wirkstoffen und/oder starken Immunsuppressiva wird nicht vergütet.<br>\\nEine Weiterbehandlung mit ZEPOSIA nach einer Therapiedauer von einem Jahr bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nDie Bristol-Myers Squibb SA erstattet in der Indikation Colitis Ulcerosa dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung ZEPOSIA einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt.<br>\\nDie Mehrwertsteuer kann nicht zusätzlich zu den Rückvergütungsbeträgen zurückgefordert werden.<br>\\nDie Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21065.02<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21065.02\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-10-01\",\"validTo\":\"2026-09-30\"}]",
  "galenic_form": "Kaps 4 x 0.23 mg 3 x 0.46 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2020-09-01",
  "self_retention_pct": 10
}

See everything about ozanimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.